Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 14;9(10):e109924.
doi: 10.1371/journal.pone.0109924. eCollection 2014.

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia

Mariana Maschietto  1 , Richard D Williams  1 , Tasnim Chagtai  1 , Sergey D Popov  2 , Neil J Sebire  3 , Gordan Vujanic  4 , Elizabeth Perlman  5 , James R Anderson  6 , Paul Grundy  7 , Jeffrey S Dome  8 , Kathy Pritchard-Jones  1
Affiliations

TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia

Mariana Maschietto et al. PLoS One. .

Abstract

Purpose: The presence of diffuse anaplasia in Wilms tumours (DAWT) is associated with TP53 mutations and poor outcome. As patients receive intensified treatment, we sought to identify whether TP53 mutational status confers additional prognostic information.

Patients and methods: We studied 40 patients with DAWT with anaplasia in the tissue from which DNA was extracted and analysed for TP53 mutations and 17p loss. The majority of cases were profiled by copy number (n = 32) and gene expression (n = 36) arrays. TP53 mutational status was correlated with patient event-free and overall survival, genomic copy number instability and gene expression profiling.

Results: From the 40 cases, 22 (55%) had TP53 mutations (2 detected only after deep-sequencing), 20 of which also had 17p loss (91%); 18 (45%) cases had no detectable mutation but three had 17p loss. Tumours with TP53 mutations and/or 17p loss (n = 25) had an increased risk of recurrence as a first event (p = 0.03, hazard ratio (HR), 3.89; 95% confidence interval (CI), 1.26-16.0) and death (p = 0.04, HR, 4.95; 95% CI, 1.36-31.7) compared to tumours lacking TP53 abnormalities. DAWT carrying TP53 mutations showed increased copy number alterations compared to those with wild-type, suggesting a more unstable genome (p = 0.03). These tumours showed deregulation of genes associated with cell cycle and DNA repair biological processes.

Conclusion: This study provides evidence that TP53 mutational analysis improves risk stratification in DAWT. This requires validation in an independent cohort before clinical use as a biomarker.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Consort diagram showing the 40 cases of diffuse anaplastic Wilms tumour used for the survival analysis by TP53 mutation and/or 17p loss.
Figure 2
Figure 2. Patients with diffuse anaplastic WT.
(A) Event-free survival (p = 0.02) and (B) overall survival curves (p = 0.02) for patients with wtTP53 (dashed line) versus mutTP53 (solid line). Numbers at risk are plot every year. HR: hazard ratio, CI: confidence interval.
See this image and copyright information in PMC

References

    1. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, et al. (1998) Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16: 3744–3751. - PubMed
    1. Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, et al. (2001) Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 19: 3719–3724. - PubMed
    1. Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, et al. (2004) Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer 101: 1072–1080. - PubMed
    1. de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, et al. (2004) Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364: 1229–1235. - PubMed
    1. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, et al. (2003) Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21: 3269–3275. - PubMed

Publication types

MeSH terms